News

Filter

1 to 9 of 36 results

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

09-12-2014

US biotech giant Amgen saw its shares rise 1.9% to $172.00 yesterday after the top US patent appeal court…

AmgenAnti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiosimilarsCubicinCubist PharmaceuticalsEnbrelGenericsHospiraLegalNovartisPatentsSandozUSA

Novartis announces positive results for secukinumab in psoriatic arthritis

Novartis announces positive results for secukinumab in psoriatic arthritis

17-11-2014

Swiss drug major Novartis has announced results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

Novartis' secukinumab achieves primary endpoints in Phase III studies for ankylosing spondylitis

23-10-2014

Swiss drug major Novartis says its investigational drug AIN457 (secukinumab) has achieved the primary…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

Novartis' secukinumab meets primary and secondary endpoints in Phase III psoriatic arthritis trials

25-09-2014

Swiss drug major Novartis' AIN457 (secukinumab) has met the primary and key secondary endpoints in two…

Anti-Arthritics/RheumaticsDermatologicalsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10-09-2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in…

AbbVieAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyEli LillyEuropeHumiraJapanMarkets & MarketingNovartisOtezlaStelaraUSAXeljanz

EU approval for Ilaris in active systemic juvenile idiopathic arthritis

03-09-2013

Following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegeneronRegulation

Two CHMP positives for Novartis

29-07-2013

There was a flow of positive news from the European Medicines Agency on Friday (July 26) for Swiss drug…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegulationRespiratory and PulmonaryUltibro BreezhalerVectura

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

1 to 9 of 36 results

COMPANY SPOTLIGHT

Menarini

Back to top